Gut Microbiome Membrane Lipids and Bile Acids Relate to Peanut Oral Immunotherapy Outcomes

Abstract

The Peanut Oral Immunotherapy in Children (IMPACT) trial, a randomized, double-blinded, placebo-controlled study achieved the primary endpoints of desensitisation (D+) in 71% or desensitization and remission (D+R+) in 21% of children treated with peanut oral immunotherapy (POIT). Variance in the gut microbiome relates to allergy and asthma status in childhood. We sought to identify functional and metabolic features of the gut microbiome that relate to the primary clinical endpoints in the IMPACT trial.